Cytori Therapeutics Inc Stock Nasdaq
Stocks
US23283K1051
Biotechnology & Medical Research
| Market Cap | 12.14M 10.79M 10.06M 9.17M 17.3M 1.17B 17.46M 122M 47.26M 596M 45.59M 44.6M 1.92B | P/E 2026 * |
-0.34x | P/E 2027 * | -0.64x |
|---|---|---|---|---|---|
| Enterprise Value | 12.14M 10.79M 10.06M 9.17M 17.3M 1.17B 17.46M 122M 47.26M 596M 45.59M 44.6M 1.92B | EV / Sales 2026 * |
3.26x | EV / Sales 2027 * | 0.63x |
| Free-Float |
98.2% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Cytori Therapeutics Inc
| 1 day | -1.85% |
| Manager | Title | Age | Since |
|---|---|---|---|
Marc Hedrick
CEO | Chief Executive Officer | 64 | 02/04/2014 |
Andrew Sims
DFI | Director of Finance/CFO | 52 | 06/02/2020 |
Daniel Ortega
CTO | Chief Tech/Sci/R&D Officer | - | 21/10/2025 |
| Director | Title | Age | Since |
|---|---|---|---|
Marc Hedrick
BRD | Director/Board Member | 64 | 01/10/2002 |
Richard Hawkins
CHM | Chairman | 77 | 25/01/2018 |
| Director/Board Member | 66 | 01/01/2020 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -1.85% | -29.07% | - | - | 12.14M | |
| +4.16% | +3.04% | +49.37% | +94.17% | 74.16B | |
| -3.11% | -3.53% | +21.92% | +74.60% | 57.39B | |
| +0.89% | -0.63% | +4.28% | +34.51% | 47.64B | |
| +0.36% | +0.81% | +352.17% | +689.61% | 44.29B | |
| -0.96% | -4.50% | +26.36% | +33.18% | 42.5B | |
| -0.20% | -0.77% | +3.74% | +100.60% | 40.71B | |
| -0.54% | +2.93% | +9.31% | +50.41% | 30.97B | |
| -2.68% | +2.92% | +29.63% | +19.50% | 28.53B | |
| +0.05% | -1.64% | -7.28% | -14.06% | 24.34B | |
| Average | -0.39% | -0.59% | +54.39% | +120.28% | 43.39B | |
| Weighted average by Cap. | +0.12% | -0.84% | +58.77% | +129.91% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 3.72M 3.31M 3.08M 2.81M 5.3M 358M 5.35M 37.35M 14.48M 183M 13.96M 13.66M 587M | 19.14M 17.01M 15.86M 14.46M 27.27M 1.84B 27.53M 192M 74.5M 940M 71.86M 70.3M 3.02B |
| Net income | -32.63M -29.01M -27.04M -24.65M -46.49M -3.14B -46.93M -328M -127M -1.6B -123M -120M -5.15B | -19.05M -16.94M -15.79M -14.39M -27.15M -1.83B -27.41M -191M -74.16M -936M -71.54M -69.98M -3.01B |
| Net Debt | - | - |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
